202 related articles for article (PubMed ID: 30206768)
1. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
2. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.
Zhou GB; Kang H; Wang L; Gao L; Liu P; Xie J; Zhang FX; Weng XQ; Shen ZX; Chen J; Gu LJ; Yan M; Zhang DE; Chen SJ; Wang ZY; Chen Z
Blood; 2007 Apr; 109(8):3441-50. PubMed ID: 17197433
[TBL] [Abstract][Full Text] [Related]
3. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.
Zhen T; Wu CF; Liu P; Wu HY; Zhou GB; Lu Y; Liu JX; Liang Y; Li KK; Wang YY; Xie YY; He MM; Cao HM; Zhang WN; Chen LM; Petrie K; Chen SJ; Chen Z
Sci Transl Med; 2012 Mar; 4(127):127ra38. PubMed ID: 22461642
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine deregulates
Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
Cao J; Feng H; Ding NN; Wu QY; Chen C; Niu MS; Chen W; Qiu TT; Zhu HH; Xu KL
Cancer Med; 2016 Nov; 5(11):3205-3213. PubMed ID: 27709797
[TBL] [Abstract][Full Text] [Related]
6. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
7. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
8. Polyphyllin I Inhibits Proliferation and Induces Apoptosis by Downregulating AML1-ETO and Suppressing C-KIT/Akt Signaling in t(8;21) Acute Myeloid Leukemia.
Chai Y; Si Y; Xu J; Xiang Y; Zhao H; Si Y; Zhang T; Liu Y
Chem Biodivers; 2018 Nov; 15(11):e1800314. PubMed ID: 30194712
[TBL] [Abstract][Full Text] [Related]
9. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
[TBL] [Abstract][Full Text] [Related]
10. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
[TBL] [Abstract][Full Text] [Related]
11. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
[TBL] [Abstract][Full Text] [Related]
12. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
Chen L; Li D; Guo X; Cheng C; Wei X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
[TBL] [Abstract][Full Text] [Related]
13. A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells.
Shi M; Ren X; Wang X; Wang H; Liu G; Yuan X; Zheng S; Yu L; Pan S; Song G; Guo Q; Li L; Zhang X; Zhang Z; Ding H; Jiang G
Int J Oncol; 2016 Feb; 48(2):734-46. PubMed ID: 26676928
[TBL] [Abstract][Full Text] [Related]
14. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
Qiu Y; Bai L; Zhao H; Mei X
BMC Cancer; 2024 Apr; 24(1):520. PubMed ID: 38658865
[TBL] [Abstract][Full Text] [Related]
15. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
16. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
[TBL] [Abstract][Full Text] [Related]
17. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
[TBL] [Abstract][Full Text] [Related]
19. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
20. Oridonin Could Inhibit Inflammation and T-cell Immunoglobulin and Mucin-3/Galectin-9 (TIM-3/Gal-9) Autocrine Loop in the Acute Myeloid Leukemia Cell Line (U937) as Compared to Doxorubicin.
Nasri F; Sadeghi F; Behranvand N; Samei A; Bolouri MR; Azari T; Abdollahi E; Ghazizadeh F; Motevalian M; Hassan ZM; Falak R
Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):602-611. PubMed ID: 33463129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
